Company: HURA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-313799
Chunk: 5

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-12-10
Form: 424B5
Chunk 5
---
estimate,” “predict,” “potential”, or “continue” or the negative of these terms or other similar expressions. Such forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, those described below:

| • |     | our ability to raise funds for general corporate purposes and operations, including our research activities and 
 clinical studies;                                                                                               |

| • |     | our ability to realize the anticipated benefits of the merger (the “Kineta Merger”) with Kineta, Inc. 
 (“Kineta”) that closed in June 2025;                                                                  |

| • |     | unexpected costs, charges or expenses resulting from the Kineta Merger; |

| • |     | the cost, timing, scope and results of our clinical studies; |

| • |     | existing regulations and regulatory developments in the United States and other jurisdictions; |

| • |     | our ability to attract and retain key scientific, medical, commercial and management personnel; |

| • |     | our ability to obtain and maintain required regulatory approvals for our products; |

| • |     | our expectations regarding the use of our existing cash; |

| • |     | the therapeutic potential of IFx-Hu2.0,                                                  
 IFx-Hu3.0, TBS-2025, our Delta Opioid Receptor technology and future product candidates; |

| • |     | the regulatory approval processes of the U.S. Food and Drug Administration and other comparable foreign                                                                                                                                                
 regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or 
 will be delayed in commercializing, such product candidates, and our ability to generate revenue will be materially impaired;                                                                                                                          |

| • |     | our ability to obtain or maintain patents or other appropriate protection for the intellectual property utilized 
 in our current and planned products; and                                                                         |

| • |     | our ability to develop and commercialize products without infringing the intellectual property rights of third 
 parties.                                                                                                       |

While we believe these expectations, assumptions, beliefs, estimates, projections, intentions and strategies are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, most of which are difficult to predict